Frontiers in Pharmacology (Nov 2024)

Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran

  • Zhuan Yang,
  • Zhuan Yang,
  • Wen Rui Tan,
  • Qin Li,
  • Ying Wang,
  • Shijing Liu,
  • Lu Chen,
  • Yan Zhou,
  • Chen Zeng,
  • Yan Zeng,
  • Yun Xiong,
  • Qian Zhang,
  • Na Li,
  • Peng Du,
  • Lin Liu,
  • Jiyu Chen,
  • Jiyu Chen,
  • Yan He,
  • Yan He

DOI
https://doi.org/10.3389/fphar.2024.1454612
Journal volume & issue
Vol. 15

Abstract

Read online

PurposeThe impact of genetic polymorphisms in the ABCB1 and CES1 genes on dabigatran plasma concentrations remains a subject of debate, and the purpose of this study was to quantitatively assess the effects of genetic polymorphisms on dabigatran esters in healthy Chinese subjects employed a population pharmacokinetic (PopPK) approach.MethodsIn total, 1,926 pharmacokinetic (PK) samples from 123 healthy individuals who were given 150 mg of dabigatran orally during a fasting state or postprandially were analyzed using the PopPK model. A two-compartment model with first-order absorption was found to adequately describe the PK data.ResultsThe results showed that covariates food intake and ABCB1 SNP rs4148738 were shown to have statistically significant impacts. Specifically, in postprandial administration increased lag time (ALAG) and clearance (CL) by 2.65% and 0.51%, respectively, and decreased absorption rate constant (KA) by 0.24%. Additionally, in subjects with CT genotype ABCB1 (rs4148738), the central ventricular volume of distribution (V2) was increased by 0.38%.ConclusionIn summary, the PopPK model developed in this study was robust and effectively characterized the pharmacokinetics of dabigatran in healthy Chinese adults, demonstrating that both food and ABCB1 genetic variation significantly influence the absorption and plasma concentration levels of dabigatran.

Keywords